Jan 26,2015

FDA Approves Dexcom G4 Platinum Continuous Glucose Monitoring System with Share

Dexcom announced today that it has received U.S. Food and Drug Administration (FDA) approval for its Dexcom G4® PLATINUM Continuous Glucose Monitoring System with Share. The Dexcom Share receiver uses a secure wireless connection via Bluetooth Low Energy (BLE) between a patient's receiver and an app on the patient's smartphone to transmit glucose information to apps on the mobile devices of up to five designated recipients, or "followers," without the need for a dedicated docking cradle. These followers can remotely monitor a patient's glucose information and receive alert notifications from almost anywhere, initially via their Apple® iPhone® or iPod® touch and in the future on Android devices, giving them peace of mind and reassurance when they are apart. The "Share" and "Follower" apps will be available on the Apple App Store at no charge.

REGULATORY FDA

#cgm

#mobile app

View Analyst & Ambassador Comments
Go to original news
Feb 17,2015

CDS tool maker for diabetes docs seeks FDA approval

ALR Technologies, which markets the Health-e-Connect chronic care platform, is seeking U.S. Food and Drug Administration 510(k) approval for the Insulin Dose Adjustment Consultation (IDAC) feature. Company officials say the new tool would draw data from a diabetic's blood glucose meter, his or her height and weight and insulin dose history, feed it through an algorithm and give doctors a real-time guideline on how much insulin to prescribe at a given moment.

PRODUCT

#bgm

View Analyst & Ambassador Comments
Go to original news
Feb 03,2015

Insulet Extends Exclusive Agreement for Blood Glucose Monitoring

Insulet Corporation (NASDAQ: PODD), the leader in tubeless insulin pump technology with its OmniPod Insulin Management System, today announced that it has extended its ongoing exclusive agreement with Abbott Laboratories to continue integration of the Abbott FreeStyle blood glucose monitoring technology with Insulet's OmniPod System.

COLLABORATION PARTNERSHIP

#connected device

#insulin pump

#bgm

View Analyst & Ambassador Comments
Go to original news
Feb 04,2015

Insulet Corporation to Present at the 2015 Leerink Global Healthcare Conference

Insulet Corporation (NASDAQ: PODD), the leader in tubeless insulin pump technology with its OmniPod® Insulin Management System, today announced that management will present at the 2015 Leerink Global Healthcare Conference in New York City on Wednesday, February 11, 2015 at 11:05 a.m. EST.

CONFERENCES
View Analyst & Ambassador Comments
Go to original news
Feb 05,2015

BD Announces Results For 2015 First Fiscal Quarter

BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today reported quarterly revenues of $2.051 billion for the first fiscal quarter ended December 31, 2014, representing an increase of 1.8 percent from the prior-year period, or 5.3 percent on a foreign currency-neutral basis.

View Analyst & Ambassador Comments
Go to original news
Feb 05,2015

Insulet Corporation to Report Fourth Quarter and Full Year 2014 Financial Results on February 26, 2015

Insulet Corporation (NASDAQ: PODD), the leader in tubeless insulin pump technology with its OmniPod® Insulin Management System, today announced plans to release its financial results for the fourth quarter and full year 2014 on February 26, 2015 after the close of the financial markets.

View Analyst & Ambassador Comments
Go to original news
Feb 05,2015

Bilan features 1Drop Diagnostics in top 50 most investable start-ups

Bilan Magazine, the foremost publication covering the Swiss economy, has featured 1Drop as one of the 50 most investable start-ups in Switzerland. 1Drop is one of eight start-ups that have been recommended by multiple jury members.

View Analyst & Ambassador Comments
Go to original news
Feb 10,2015

Insulet Further Enhances Executive Leadership Team to Drive Improved Commercial and Operational Performance

Insulet Corporation (NASDAQ: PODD), the leader in tubeless insulin pump technology with its OmniPod® Insulin Management System, today announced the appointment of Daniel Levangie to the newly-created role of President, Insulet Drug Delivery, and Ms. Shacey Petrovic to the position of Chief Commercial Officer, both reporting directly to Patrick Sullivan, President and Chief Executive Officer. As President, Insulet Drug Delivery, Mr. Levangie will focus on developing new growth opportunities for use of the OmniPod technology in the administration of a range of pharmaceutical products.

View Analyst & Ambassador Comments
Go to original news
Feb 10,2015

Insulet Appoints John Fallon, M.D. as New Lead Director

Insulet Corporation (NASDAQ: PODD), the leader in tubeless insulin pump technology with its OmniPod® Insulin Management System, today announced that Dr. John Fallon has been appointed Lead Director of Insulet's Board of Directors. Dr. Fallon has served on the Insulet Board since 2012 and replaces Daniel Levangie who is resigning from the Insulet Board in order to assume the newly-created role of President, Insulet Drug Delivery.

View Analyst & Ambassador Comments
Go to original news
Feb 10,2015

Tandem Diabetes Care Schedules Fourth Quarter and Full Year 2014 Earnings Press Release and Conference Call

Tandem Diabetes Care®, Inc. (Nasdaq:TNDM), a medical device company and manufacturer of the t:slim® and t:flex™ Insulin Pumps, plans to release its fourth quarter and full year 2014 results after the financial markets close on Tuesday, February 24, 2015. The Company will hold a conference call and simultaneous webcast on the same day at 4:30pm Eastern Time (1:30pm Pacific Time), to discuss its fourth quarter and full year 2014 financial and operating results.

View Analyst & Ambassador Comments
Go to original news
Subscribe to DIABETES